A Trial to Examine the Effects of MSP-2020 on Brain Activity in Healthy Adults

2025-522930-29-00 Protocol 358-201-00001 Human pharmacology (Phase I) - Other Ongoing, recruiting

Start 17 Nov 2025 · Status Ongoing, recruiting · 1 EU/EEA countries · 1 sites · Protocol 358-201-00001

Overview

Sponsor-declared trial summary

Phase Human pharmacology (Phase I) - Other
Status Ongoing, recruiting
Participants planned 72
Countries 1
Sites 1

Incomplete Response - Major Depressive Disorder (IR-MDD)

Key facts

Sponsor
Otsuka Pharmaceutical Development & Commercialization Inc.
Participant type
Healthy volunteers
Age range
18-64 years
Gender
Male and Female
Therapeutic area
Psychiatry and Psychology [F] - Mental Disorders [F03]
Trial duration
17 Nov 2025 → ongoing
Decision date (initial)
2025-10-31
Transition trial
No
Low-intervention
No
Rare-disease indication
No
Vulnerable population
No

Trial design

CTIS Part I — objectives, methods, condition coding

Conditions and MedDRA coding

Incomplete Response - Major Depressive Disorder (IR-MDD)

VersionLevelCodeTermSystem organ class
21.1 LLT 10081270 Major depressive disorder 10037175

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Otsuka Pharmaceutical Development & Commercialization Inc.

Sponsor organisation
Otsuka Pharmaceutical Development & Commercialization Inc.
Address
2440 Research Boulevard
City
Rockville
Postcode
20850-3238
Country
United States

Scientific contact point

Organisation
Otsuka Pharmaceutical Development & Commercialization Inc.
Contact name
EU Clinical Trials Helpdesk

Public contact point

Organisation
Otsuka Pharmaceutical Development & Commercialization Inc.
Contact name
EU Clinical Trials Helpdesk

Locations

1 EU/EEA country · 1 investigational sites

By country

CountryMS statusPlanned subjectsSites
Netherlands Ongoing, recruiting 72 1
Rest of world 0

Investigational sites

Netherlands

1 site · Ongoing, recruiting
Centre for Human Drug Research
Psychiatry, Zernikedreef 8, 2333 CL, Leiden

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Country Trial startTrial end Recruitment startRecruitment end Early termination
Netherlands 2025-11-17 2025-11-17

Application history

5 submissions — initial application plus substantial / non-substantial modifications

#TypeCodeSubmittedReference MSConclusionDecision date
1 INITIAL IN 2025-08-22 Netherlands Acceptable
2025-10-31
2025-10-31
2 NON SUBSTANTIAL MODIFICATION NSM-2 2025-12-03 Netherlands Acceptable
2025-10-31
2025-12-03
3 NON SUBSTANTIAL MODIFICATION NSM-3 2026-01-20 Netherlands Acceptable
2025-10-31
2026-01-20
4 SUBSTANTIAL MODIFICATION SM-2 2026-04-27 Netherlands Acceptable
2026-05-13
2026-05-13
5 NON SUBSTANTIAL MODIFICATION NSM-4 2026-05-27 Netherlands Acceptable
2026-05-13
2026-05-27